BVS — Bioventus Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual income statement for Bioventus, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2018 December 31st	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	319	340	321	431	512
Cost of Revenue
Gross Profit	235	249	234	303	331
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	294	312	296	421	763
Operating Profit	25.5	28.2	25.4	9.9	-251
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	6.11	9.69	15.9	7.62	-264
Provision for Income Taxes
Net Income After Taxes	4.44	8.11	14.7	9.59	-213
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-12.2	6.85	16.4	19.4	-159
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-18	-0.659	4.38	19.4	-159
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.026	0.166	0.207	1.04	-0.055
Dividends per Share